trending Market Intelligence /marketintelligence/en/news-insights/trending/-Dv76Xp8yf2xBJmsEC6vHw2 content esgSubNav
In This List

US FDA shoots down Oxford Pharmascience's phase 3 study plan

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


US FDA shoots down Oxford Pharmascience's phase 3 study plan

The U.S. FDA shot down Oxford Pharmascience Group PLC's proposed phase 3 study design for OXPzero, the company's reformulated version of ibuprofen.

The regulator disagreed with the proposed primary endpoints of the study and asked that the company undertake a clinical trial to back claims of improved gastrointestinal safety. The study would require improvements in peptic ulcer bleeding and related complications to qualify.

Oxford could skip a clinical study altogether if it tones down the claim for the drug which would not require a detailed trial, the FDA suggested alternatively.

Oxford said it would consider the FDA suggestions carefully before a decision is made on the development program.

The company's stock price was down 32.73% to £2.04 per share as of 11:17 a.m. ET on March 31.